JNJ ▼ -1.4% - Johnson & Johnson
$JNJ - Johnson & Johnson reports 75% tumor response rate in advanced prostate cancer with JNJ-6143, a first-in-class RIPTAC™ molecule
25-OCT-2026 03:30 AM ET
Share this post
More filings for $JNJ
JNJ ▲ +1.0% - Johnson & JohnsonOct 22, 2026JNJ ▼ -0.7% - Johnson & JohnsonOct 21, 2026JNJ ▲ +0.8% - Johnson & JohnsonOct 20, 2026JNJ ▼ -0.8% - Johnson & JohnsonOct 19, 2026JNJ ▼ -0.7% - Johnson & JohnsonOct 13, 2026JNJ ▲ +0.9% - Johnson & JohnsonOct 12, 2026
View full $JNJ filing history →💬 Comments
Loading comments…
Leave a comment